Tyler Stone Wealth Management Buys 652 Shares of VanEck Biotech ETF (NASDAQ:BBH)

Tyler Stone Wealth Management increased its position in shares of VanEck Biotech ETF (NASDAQ:BBH) by 79.5% during the 3rd quarter, Holdings Channel reports. The fund owned 1,472 shares of the company’s stock after buying an additional 652 shares during the quarter. Tyler Stone Wealth Management’s holdings in VanEck Biotech ETF were worth $261,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Mather Group LLC. acquired a new position in shares of VanEck Biotech ETF in the 2nd quarter valued at $46,000. Red Lighthouse Investment Management LLC bought a new position in VanEck Biotech ETF during the second quarter worth about $51,000. Hyman Charles D acquired a new position in VanEck Biotech ETF in the second quarter valued at about $202,000. Truist Financial Corp increased its holdings in shares of VanEck Biotech ETF by 3.8% in the second quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after acquiring an additional 100 shares in the last quarter. Finally, Atlas Capital Advisors LLC acquired a new stake in shares of VanEck Biotech ETF during the second quarter worth about $960,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Down 1.1 %

Shares of BBH opened at $172.90 on Tuesday. The stock has a 50 day simple moving average of $175.93 and a 200 day simple moving average of $173.01. VanEck Biotech ETF has a 52-week low of $146.10 and a 52-week high of $183.64.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.